Xermelo

Xermelo contains the active ingredient telotristat etiprate and is used to manage symptoms associated with carcinoid syndrome, a condition caused by certain types of neuroendocrine tumors. Carcinoid syndrome occurs when tumors release excess serotonin and other chemicals into the bloodstream, leading to frequent diarrhea, flushing, and abdominal discomfort. It works by inhibiting an enzyme called tryptophan hydroxylase, which is responsible for producing serotonin. Reducing serotonin production, it helps decrease the severity and frequency of diarrhea and other related symptoms, improving overall quality of life.
The medication is administered orally in tablet form, allowing the active ingredient to enter the bloodstream efficiently and act on the enzyme system. Xermelo is generally used alongside standard care for carcinoid syndrome to better control persistent symptoms that are not fully managed by other treatments. Its targeted mechanism focuses on symptom relief without directly affecting tumor growth.
Common effects may include nausea, abdominal pain, constipation, headache, and fatigue. Some individuals may experience mild swelling, elevated liver enzymes, or mood changes. Rarely, serious complications such as severe gastrointestinal issues or allergic reactions can occur. Regular monitoring by a healthcare professional is recommended to assess symptom improvement and detect any adverse effects early.
Xermelo is not intended to treat the tumor itself but to provide relief from the burdensome symptoms caused by excess serotonin. Its use allows individuals with carcinoid syndrome to maintain better daily functioning, reduce discomfort, and improve overall well-being while managing the complex effects of this condition.